Last updated: April 25, 2026
Bayer HealthCare LLC v. Mylan Pharmaceuticals Inc. (1:15-cv-00114): Litigation Summary and Patent-Use Analysis
What is the case and what claims were in play?
Bayer HealthCare LLC v. Mylan Pharmaceuticals Inc., No. 1:15-cv-00114 (D. Delaware), is a federal Hatch-Waxman patent litigation matter in which Bayer (patent owner) challenged Mylan’s ANDA with respect to a Bayer drug product under 35 U.S.C. § 271(e)(2). The suit targets Mylan’s planned commercial entry upon ANDA approval by alleging that Mylan’s ANDA filing would infringe Bayer’s asserted patents and/or that Mylan’s non-infringement and invalidity positions lack merit.
Procedural posture and key litigation function: this type of action is built around the ANDA approval pathway and focuses on whether Mylan’s “Paragraph IV” (or equivalent) patent notice positions are legally and technically correct. The litigation typically resolves via claim construction and summary judgment or a trial record on infringement/invalidity.
What did the parties dispute at the patent level?
The core disputes in this case track standard Hatch-Waxman infringement and invalidity content, including:
- Infringement of asserted claims: Whether Mylan’s ANDA product, as described in the ANDA and related submissions, meets claim limitations of the asserted Bayer patents.
- Validity defenses: Whether asserted claims are invalid for reasons commonly raised in this forum, including lack of novelty, obviousness, or improper patenting.
- Non-infringement defenses: Whether the ANDA product avoids claim elements or fails to meet claim construction requirements.
- Legal defenses tied to the notice/ANDA framework: Whether Bayer’s assertions align with the statute’s claim-to-ANDA infringement framework.
Bayer’s litigation objective was to obtain an adjudication that would block or delay approval for Mylan’s generic entry until expiration of the asserted patent rights (or until a judgment eliminates the blocking effect).
What does the “AND A + § 271(e)(2)” framework mean for infringement proof?
For Hatch-Waxman patent cases, the infringement inquiry is not about past sales. It is a specific statutory construct: infringement is measured by the act of submitting the ANDA to engage in conduct that would infringe if the generic product were made, used, or sold after approval. Under 35 U.S.C. § 271(e)(2), the legal question is whether the ANDA filing contains certifications and information that, when combined with the technical description of the proposed product, would infringe the asserted patents upon commercial manufacture and use.
This matters for business analysis because the litigation record is often driven by:
- Claim construction (what the claims mean)
- Comparison of the proposed ANDA product to claim limitations
- Expert reports anchored to the ANDA description, label, and formulation/manufacturing features
How does the Delaware venue typically shape the litigation?
In D. Delaware, courts usually resolve Hatch-Waxman actions through a sequence that emphasizes:
- Fast claim construction scheduling
- Early summary-judgment opportunities (in whole or in part)
- A trial record focused on the asserted patents and the specific claim elements at issue
For investors and R&D leaders, that means case outcomes often hinge on a limited number of claim constructions and tight technical disputes rather than broad, open-ended theory.
What is the likely economic and timing impact?
In a Hatch-Waxman action, the economic impact is tied to:
- Whether infringement and validity defenses are resolved in Bayer’s favor for any asserted patents, which can trigger a statutory delay on approval
- Whether the court narrows or invalidates key claims, reducing the blocking effect or eliminating it
In practice, a partial outcome (some claims upheld, others invalidated) can still create:
- A partial injunction against approval, or
- A changed landscape where design-arounds and new formulations still risk infringement on remaining claims
What is the patent-use analysis relevant to a generic challenger (Mylan)?
Patent-use analysis for a generic challenger centers on two questions the court’s record typically answers:
1) Claim coverage
- Are the asserted claims drafted broadly enough that the proposed ANDA product hits the construed limitations?
- Do the claims rely on features that are difficult to change in a generic (for example, stability, release characteristics, composition parameters tied to the active ingredient or formulation)?
2) Validity durability
- Even if the product reads on the claims, can Bayer’s patents withstand invalidity attacks?
- Are the asserted claims anchored to prior art, obviousness combinations, or enablement issues?
Because this is a business-critical litigation, Mylan’s risk management usually aligns with:
- Seeking invalidation early for high-value patents
- Narrowing claim construction
- Identifying non-infringing design-around pathways if any patents survive
What is the patent-use analysis relevant to Bayer (patent owner)?
Bayer’s patent-use analysis is built around:
- Establishing that the ANDA product matches the construed claim limitations
- Defending validity by maintaining that the asserted claims are distinguishable from prior art and that the claims are properly supported
- Ensuring the asserted claim set stays tight enough that it is not vulnerable across multiple prior-art avenues
The business objective is to keep enough enforceable claim coverage in place to sustain the statutory blocking effect long enough for market exclusivity, life-cycle strategy, or additional patent layers to control entry.
Key litigation artifacts to track in this case
Even when a case does not publicly disclose complete technical details in early filings, the decision record in Hatch-Waxman matters typically turns on these artifacts:
| Litigation artifact |
What it does in the case |
What business teams use it for |
| Complaint and asserted patents |
Identifies claim scope Bayer relies on |
Maps what patents are blocking and what product features matter |
| ANDA certification notice (Paragraph IV or equivalent) |
Frames the legal basis for challenge |
Assesses whether the dispute is validity-only or infringement+validity |
| Claim construction briefs |
Locks in claim meaning |
Predicts infringement risk and defines design-around boundaries |
| Expert reports |
Bridge between legal claim elements and technical ANDA facts |
Quantifies technical infringement vectors and key failure points |
| Dispositive motions |
Resolves infringement and validity in whole or part |
Determines whether the case ends early or proceeds to trial |
| Trial record / final judgment |
Provides binding outcomes on asserted claims |
Determines which patents remain enforceable and which do not |
Why this case matters for investment and R&D planning
This action’s practical relevance is that it directly determines:
- Whether Mylan’s ANDA approval is delayed or blocked for specific asserted patents
- Whether a generic entry strategy remains viable if some patents survive
- Whether Bayer’s patent portfolio strategy is validated (if claims survive, Bayer’s portfolio strength in this therapeutic area is reinforced)
For portfolio managers, the case also informs:
- The durability of similar claim types in later challenges
- How courts are construing claim elements tied to formulation or manufacturing
- The likelihood that other generics will face similar infringement barriers
Key Takeaways
- The case is a Hatch-Waxman ANDA patent infringement action under 35 U.S.C. § 271(e)(2) in D. Delaware, No. 1:15-cv-00114, brought by Bayer HealthCare LLC against Mylan Pharmaceuticals Inc.
- The dispute is structured around whether Mylan’s ANDA product would infringe Bayer’s asserted patents upon approval and whether those patents are valid over the asserted prior art and legal challenges.
- Outcome value is driven by which asserted claims survive claim construction and validity challenges, because that determines the blocking effect on approval and impacts design-around feasibility.
FAQs
What court decided Bayer HealthCare LLC v. Mylan Pharmaceuticals Inc.?
It is filed in the U.S. District Court for the District of Delaware under No. 1:15-cv-00114.
What statute governs the infringement theory in Hatch-Waxman ANDA cases?
The infringement theory is under 35 U.S.C. § 271(e)(2), which makes the act of filing certain ANDAs an act of patent infringement.
What are the two biggest questions the court addresses in this type of case?
Whether the ANDA product infringes the asserted claims and whether the asserted patents are valid against the legal and prior-art challenges.
How does the result affect generic approval timing?
A judgment upholding infringement for one or more asserted patents generally sustains a statutory delay (and may support injunctive effects), while invalidation or non-infringement eliminates or reduces blocking patents.
What evidence typically drives outcomes in ANDA patent cases?
Claim construction, ANDA technical descriptions and product characterization, and expert testimony mapped to claim limitations.
References (APA)
[1] 35 U.S.C. § 271(e)(2).
